Neurology

The FDA has granted a landmark approval to an intravenous injection for the imaging of tau pathology among patients with cognitive impairment being evaluated for Alzheimer disease.

It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.

Three applications for the first generic capsules have been granted by the US Food and Drug Administration.

This approval comes after the drug was found to be safe and effective in 2 randomized, double-blind, placebo-controlled trials including 655 adults with partial-onset seizures.

After a clinical trial showed the treatment was more effective than placebo, the FDA approved the first treatment for episodic cluster headache in adults that reduces the frequency of attacks.

The medication is to be used as an adjunctive therapy in adult and pediatric patients with complex partial seizures.

The FDA has released a warning about the potential for an increase in disability in patients with multiple sclerosis who stop taking this immunosuppressant.

The new humanized monoclonal antibody acts by reducing the effect of CGRP, which is believed to have a physiologic role in migraine.

The FDA has approved a new migraine injection available in weekly and monthly dosing options.

The FDA has approved a new drug for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy.